What are Premixed insulin drugs?

Premixed insulin drugs are pharmacologic agents that share a common mechanism (typically targeting Insulin receptor). 4 are currently marketed, with 1 more in clinical development.

What are the marketed Premixed insulin drugs?

Marketed Premixed insulin drugs include BIAsp30, Insulin Biphasic Aspart 30/70, Scilin®M30, insulin lispro LM.

Premixed insulin

4 marketed 1 in Phase 3

This page covers all Premixed insulin drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Insulin receptor.

Targets

Insulin receptor

Marketed (4)

BIAsp30 · The First Hospital of Jilin University · Diabetes
BIAsp30 is a biphasic insulin aspart formulation that provides both rapid-acting and intermediate-acting insulin coverage to control blood glucose levels.
Insulin Biphasic Aspart 30/70 · Eli Lilly and Company · Diabetes
Insulin biphasic aspart 30/70 is a premixed insulin combining 30% rapid-acting aspart and 70% intermediate-acting aspart to provide both immediate and sustained blood glucose control.
Scilin®M30 · Chinese Diabetes Society · Diabetes
Scilin®M30 is a premixed insulin formulation that combines rapid-acting and intermediate-acting insulin to control blood glucose in diabetes.
insulin lispro LM · Eli Lilly and Company · Diabetes
Insulin lispro LM is a premixed insulin formulation that combines rapid-acting insulin lispro with intermediate-acting insulin to provide both mealtime and basal glucose control.

Phase 3 pipeline (1)

Humalog® Mix25 · Adocia · Diabetes
Humalog® Mix25 is a premixed insulin formulation combining rapid-acting insulin lispro with intermediate-acting insulin isophane to provide both immediate and sustained blood glucose control.